NASDAQ:IMGN

ImmunoGen Competitors

$7.52
-0.18 (-2.34 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$7.41
Now: $7.52
$7.78
50-Day Range
$7.18
MA: $8.42
$9.13
52-Week Range
$3.34
Now: $7.52
$10.88
Volume858,689 shs
Average Volume2.44 million shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65

Competitors

ImmunoGen (NASDAQ:IMGN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying IMGN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to ImmunoGen, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

ImmunoGen (NASDAQ:IMGN) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Amgen091402.61

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Amgen has a consensus target price of $261.0476, suggesting a potential upside of 1.67%. Given ImmunoGen's higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Amgen.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Amgen29.42%95.55%15.52%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Amgen$23.36 billion6.30$7.84 billion$14.8217.25

Amgen has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats ImmunoGen on 10 of the 14 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Gilead Sciences191302.52

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Gilead Sciences has a consensus target price of $97.92, suggesting a potential upside of 47.58%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than ImmunoGen.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Gilead Sciences5.48%37.77%12.76%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Gilead Sciences$22.45 billion3.75$5.39 billion$6.1410.89

Gilead Sciences has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats ImmunoGen on 10 of the 14 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Vertex Pharmaceuticals042112.88

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 32.98%. Given ImmunoGen's higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Vertex Pharmaceuticals38.51%28.55%20.68%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Vertex Pharmaceuticals$4.16 billion13.64$1.18 billion$4.2951.14

Vertex Pharmaceuticals has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats ImmunoGen on 11 of the 15 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Regeneron Pharmaceuticals051412.80

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.80%. Given ImmunoGen's higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Regeneron Pharmaceuticals.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ImmunoGen and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41

Regeneron Pharmaceuticals has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats ImmunoGen on 12 of the 15 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings and Valuation

This table compares ImmunoGen and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Biogen$14.38 billion2.86$5.89 billion$33.578.05

Biogen has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ImmunoGen has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ImmunoGen and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Biogen5141202.23

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Biogen has a consensus target price of $303.5862, suggesting a potential upside of 12.12%. Given ImmunoGen's stronger consensus rating and higher probable upside, research analysts clearly believe ImmunoGen is more favorable than Biogen.

Profitability

This table compares ImmunoGen and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Biogen35.63%51.00%23.54%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Biogen beats ImmunoGen on 9 of the 14 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares ImmunoGen and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Alexion Pharmaceuticals$4.99 billion7.21$2.40 billion$9.7416.80

Alexion Pharmaceuticals has higher revenue and earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ImmunoGen has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for ImmunoGen and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Alexion Pharmaceuticals017512.30

ImmunoGen currently has a consensus target price of $10.10, suggesting a potential upside of 33.42%. Alexion Pharmaceuticals has a consensus target price of $153.8636, suggesting a potential downside of 6.17%. Given ImmunoGen's stronger consensus rating and higher probable upside, analysts clearly believe ImmunoGen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares ImmunoGen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Alexion Pharmaceuticals16.32%23.16%14.76%

Institutional & Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 3.8% of ImmunoGen shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Alexion Pharmaceuticals beats ImmunoGen on 11 of the 15 factors compared between the two stocks.


ImmunoGen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.71-0.2%$147.24 billion$23.36 billion20.62Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.87-1.6%$84.19 billion$22.45 billion68.94Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39-0.8%$56.78 billion$4.16 billion27.70
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.60-1.6%$53.84 billion$7.86 billion18.37Analyst Report
Biogen logo
BIIB
Biogen
1.9$270.31-0.0%$41.18 billion$14.38 billion8.95Upcoming Earnings
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68-3.8%$35.98 billion$4.99 billion38.24Unusual Options Activity
News Coverage
Gap Down
Seagen logo
SGEN
Seagen
1.7$145.50-2.8%$26.38 billion$916.71 million57.28Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.04-0.4%$21.99 billion$876.29 million-58.84
Incyte logo
INCY
Incyte
1.7$82.68-0.6%$18.18 billion$2.16 billion-52.66
Novavax logo
NVAX
Novavax
1.2$227.35-11.1%$16.79 billion$18.66 million-43.55
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.29-0.5%$16.31 billion$219.75 million-17.66
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.92-0.2%$14.32 billion$1.70 billion18.06
Repligen logo
RGEN
Repligen
1.5$212.68-0.4%$11.70 billion$270.24 million259.37
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.58-1.6%$9.13 billion$788.10 million103.85Analyst Upgrade
Increase in Short Interest
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.85-1.1%$8.98 billion$1.45 billion19.29Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$23.59-1.5%$7.36 billion$967.78 million49.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.22-0.0%$6.62 billion$195.99 million288.88Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.31-5.3%$2.05 billion$638.60 million-10.50
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Codexis logo
CDXS
Codexis
1.3$23.60-4.0%$1.52 billion$68.46 million-67.43Analyst Revision
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02
Innoviva logo
INVA
Innoviva
1.4$11.64-2.1%$1.21 billion$261.02 million5.94
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
MannKind logo
MNKD
MannKind
1.4$4.23-1.7%$1.07 billion$63.04 million-20.14Increase in Short Interest
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.90-1.4%$933.33 million$3.57 million-10.72Analyst Upgrade
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36-8.8%$812.29 millionN/A0.00Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.96-5.0%$752.08 million$322.07 million-4.72Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98-2.0%$625.09 million$143.01 million-1.14
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40
Geron logo
GERN
Geron
1.4$1.47-2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.68-0.4%$461.78 million$17.46 million-1.90
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00-0.7%$461.18 million$109.33 million-2.21
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12-7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$37.06-2.1%$426.12 million$18.37 million-33.39Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.14-7.2%$421.39 million$36.63 million-4.87Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.